Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevention. Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We consider what features are needed to maximise efficiency. Populations could be selected by age, clinical or genetic risk factors or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential patients and can be measured in large trials. The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and will need collaboration between many clinical investigators, funders and patient organisations.

Original publication

DOI

10.1093/ageing/afz152

Type

Journal article

Journal

Age Ageing

Publication Date

27/02/2020

Volume

49

Pages

154 - 160

Keywords

dementia , epidemiology , function , older people , trials , Age Factors, Aged, Aged, 80 and over, Dementia, Humans, Mental Status and Dementia Tests, Patient Selection, Randomized Controlled Trials as Topic, Sample Size, Time Factors, Treatment Outcome